HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

News and Updates


There are 308 News Items in 62 pages and you are on page number 1

StockNewsNow.com Publishes SNNLive Video Interview Update with Pressure BioSciences, Inc.

LOS ANGELES, CA--(November 23, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (PBIO), a life sciences company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market, according to the Company's website (see here: www.PressureBioSciences.com). The video interview was recorded at the SeeThruEquity MicroCap Investor Forum on November 12th, 2015 in New York City, NY.

(full story)

Pressure BioSciences, Inc. Reports Record Third Quarter and Year-to-Date 2015 Financial Results

SOUTH EASTON, Mass., Nov. 12, 2015 -- Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced financial results for the three and nine-month periods ended September 30, 2015.

(full story)

Estill, SC Joins Sparta Commercial’s Municipal Lease Program

New York, NY.  October 8, 2015 - - Sparta Commercial Services, Inc. (OTCQB: SRCO) announced today that Estill, SC, with a transaction to acquire new Dodge Charger police vehicles to replace older models for its police department, is now the nineteenth and most recent jurisdiction in the Carolinas to choose Sparta's Municipal Lease Program to meet its essential equipment needs.

(full story)

Department of Defense Grants Cleveland BioLabs Second Award

Buffalo, NY – September 21, 2015 – Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Medical Research Program has awarded CBLI a research grant valued at up to $6.6 million to fund a clinical trial designed to support a Biologics License Application (BLA) for entolimod.  Entolimod is a novel, broad-spectrum investigational drug being developed to reduce the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.

(full story)

Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy

Buffalo, NY – September 16, 2015 – Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced the publication in the scientific journal, PLOS ONE, of studies demonstrating the ability of entolimod to reduce radiation injury and improve survival when the drug is administered up to 48 hours after lethal radiation exposure in nonhuman primates.


(full story)

Page:  1 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  Next >>



  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved